Approved accessible "ganaxolone"

ZTALMY is a prescription medicine that is used to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in people 2 years of age and older. • [There is a pending DEA decision for control of ZTALMY (ganaxolone) under the Controlled Substances Act. A statement for patients about abuse and dependence risks cannot be completed at this time.] • It is not known if ZTALMY is safe and effective in children under 2 years of age.

Active ingredient: ganaxolone Inactive ingredients: artificial cherry flavor, citric acid, hypromellose, methylparaben, polyvinyl alcohol, propylparaben, purified water, simethicone emulsion, sodium benzoate, sodium citrate, sodium lauryl sulfate and sucralose. Ganaxolone, sold under the brand name Ztalmy, is a medication used to treat seizures in people with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD).  Ganaxolone was approved for medical use in the United States in March 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

How can 1 go about obtaining ganaxolone?

If access ganaxolone oral suspension are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

ZTALMY (ganaxolone) oral suspension, CXX Initial U.S. Approval